〔Abstract〕 Objective To examine the effect of SNAP29 on Cisplatin resistance of gastric cancer cells, compare the expression of SNAP29 in gastric cancer and normal gastric tissues and analyze the clinicopathological significance of SNAP29 in gastric cancer patients. Methods Western blot was used to detect the SNAP29 protein levels in cell lines. MTT assay and soft agar colony formation assay were performed to detect cell viability and cell colony formation respectively, and for further examine the overexpression of SNAP29 to promote Cisplatin resistance in gastric cancer cells. Immunohistochemistry was carried out to detect the expression of SNAP29 protein in gastric cancer and normal gastric tissues, and to analyze the correlation between SNAP29 levels and pathological parameters in gastric cancer patients. Results MTT and soft agar colony formation assays showed that the overexpression of SNAP29 promoted Cisplatin resistance in gastric cancer cells MKN-45 and AGS; there was no significant difference of SNAP29 protein levels in gastric cancer and normal gastric tissue; the expression levels of SNAP29 were correlated with lymph node metastasis and tumor stage in gastric cancer patients, but not with patients' age, gender, tumor size or tumor grade. Conclusion Overexpression of SNAP29 promotes Cisplatin resistance in human gastric cancer cells. The expression levels of SNAP29 are positively correlated with lymph node metastasis and tumor stage in gastric cancer patients. Therefore, SNAP29 is an important biomarker for diagnosis and treatment in gastric cancer.